BioCentury
ARTICLE | Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

August 29, 2018 6:00 AM UTC

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed in the round.

KaNDy was spun out of NeRRe Therapeutics Ltd. (Stevenage, U.K.) in 2017 to develop NT-814, a small molecule dual antagonist of neurokinin 1 receptor (NK1R; TACR1) and NK3R, to treat symptoms associated with menopause...